Literature DB >> 21821799

Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.

Willem J J Falkenburg1, J Joseph Melenhorst, Marian van de Meent, Michel G D Kester, Pleun Hombrink, Mirjam H M Heemskerk, Renate S Hagedoorn, Emma Gostick, David A Price, J H Frederik Falkenburg, A John Barrett, Inge Jedema.   

Abstract

T cells recognizing tumor-associated Ags such as Wilms tumor protein (WT1) are thought to exert potent antitumor reactivity. However, no consistent high-avidity T cell responses have been demonstrated in vaccination studies with WT1 as target in cancer immunotherapy. The aim of this study was to investigate the possible role of negative thymic selection on the avidity and specificity of T cells directed against self-antigens. T cell clones directed against the HLA-A*0201-binding WT1(126-134) peptide were generated from both HLA-A*02-positive (self-HLA-restricted) and HLA-A*02-negative [nonself (allogeneic) HLA [allo-HLA]-restricted] individuals by direct ex vivo isolation using tetramers or after in vitro priming and selection. The functional avidity and specificity of these T cell clones was analyzed in-depth. Self-HLA-restricted WT1-specific clones only recognized WT1(126-134) with low avidities. In contrast, allo-HLA-restricted WT1 clones exhibited profound functional reactivity against a multitude of HLA-A*02-positive targets, even in the absence of exogenously loaded WT1 peptide, indicative of Ag-binding promiscuity. To characterize this potential promiscuity, reactivity of the T cell clones against 400 randomly selected HLA-A*0201-binding peptides was investigated. The self-HLA-restricted WT1-specific T cell clones only recognized the WT1 peptide. In contrast, the allo-HLA-restricted WT1-reactive clones recognized besides WT1 various other HLA-A*0201-binding peptides. In conclusion, allogeneic HLA-A*02-restricted WT1-specific T cells isolated from mismatched donors may be more tumor-reactive than their autologous counterparts but can show specific off-target promiscuity of potential clinical importance. As a result of this, administration of WT1-specific T cells generated from HLA-mismatched donors should be performed with appropriate precautions against potential off-target effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821799     DOI: 10.4049/jimmunol.1100852

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity.

Authors:  Scott M Krummey; Ryan J Martinez; Rakieb Andargachew; Danya Liu; Maylene Wagener; Jacob E Kohlmeier; Brian D Evavold; Christian P Larsen; Mandy L Ford
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

2.  RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.

Authors:  Sylvia Snauwaert; Stijn Vanhee; Glenn Goetgeluk; Greet Verstichel; Yasmine Van Caeneghem; Imke Velghe; Jan Philippé; Zwi N Berneman; Jean Plum; Tom Taghon; Georges Leclercq; Kris Thielemans; Tessa Kerre; Bart Vandekerckhove
Journal:  Haematologica       Date:  2012-04-24       Impact factor: 9.941

Review 3.  Molecular immunology lessons from therapeutic T-cell receptor gene transfer.

Authors:  Sharyn Thomas; Hans J Stauss; Emma C Morris
Journal:  Immunology       Date:  2010-02       Impact factor: 7.397

4.  T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes.

Authors:  Tomasz Kula; Mohammad H Dezfulian; Charlotte I Wang; Nouran S Abdelfattah; Zachary C Hartman; Kai W Wucherpfennig; Herbert Kim Lyerly; Stephen J Elledge
Journal:  Cell       Date:  2019-08-08       Impact factor: 41.582

5.  Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection.

Authors:  Thomas M Schmitt; David H Aggen; Ingunn M Stromnes; Michelle L Dossett; Sarah A Richman; David M Kranz; Philip D Greenberg
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

6.  Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade.

Authors:  Scott M Krummey; Tamara L Floyd; Danya Liu; Maylene E Wagener; Mingqing Song; Mandy L Ford
Journal:  J Immunol       Date:  2014-02-03       Impact factor: 5.422

7.  Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.

Authors:  Shraddha Kumari; Sébastien Wälchli; Lars-Egil Fallang; Weiwen Yang; Fridtjof Lund-Johansen; Ton N Schumacher; Johanna Olweus
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-16       Impact factor: 11.205

8.  High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept.

Authors:  S M Krummey; J A Cheeseman; J A Conger; P S Jang; A K Mehta; A D Kirk; C P Larsen; M L Ford
Journal:  Am J Transplant       Date:  2014-03       Impact factor: 8.086

9.  NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.

Authors:  Daniel Sommermeyer; Heinke Conrad; Holger Krönig; Haike Gelfort; Helga Bernhard; Wolfgang Uckert
Journal:  Int J Cancer       Date:  2012-09-14       Impact factor: 7.396

10.  Heterogeneity within T Cell Memory: Implications for Transplant Tolerance.

Authors:  Scott M Krummey; Mandy L Ford
Journal:  Front Immunol       Date:  2012-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.